BTCY Stock Overview A medical technology company, provides biometric data monitoring solutions in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Biotricity, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Biotricity Historical stock prices Current Share Price US$0.28 52 Week High US$1.67 52 Week Low US$0.19 Beta 1.11 1 Month Change -11.11% 3 Month Change -6.04% 1 Year Change -74.55% 3 Year Change -98.84% 5 Year Change -93.23% Change since IPO -98.24%
Recent News & Updates
Biotricity Kicks Off Another Pilot Program with A Major Hospital System That Services over 800,000 Individuals Sep 20 Biotricity, Inc. announced delayed 10-Q filing Aug 16
Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Aug 02 Biotricity, Inc., Annual General Meeting, Aug 15, 2024 Jul 25
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program Jul 11
Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services Jun 13 See more updates
Biotricity Kicks Off Another Pilot Program with A Major Hospital System That Services over 800,000 Individuals Sep 20 Biotricity, Inc. announced delayed 10-Q filing Aug 16
Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Aug 02 Biotricity, Inc., Annual General Meeting, Aug 15, 2024 Jul 25
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program Jul 11
Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services Jun 13 Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million. May 29
Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro Apr 27 Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million. Apr 26
Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq Apr 24
Biotricity, Inc. announced that it has received $2 million in funding Apr 10
Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities Apr 04 Biotricity, Inc. announced a financing transaction Mar 27
Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud Mar 13 Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million. Feb 29
Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million. Feb 28
Biotricity, Inc. announced delayed 10-Q filing Feb 15
Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market Feb 03
Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding Jan 26
Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats Jan 24
New major risk - Share price stability Jan 18
Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023) Nov 19
Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023 Nov 11
Biotricity Releases Another Groundbreaking Product: Biotres Pro Nov 01
New major risk - Market cap size Oct 30
Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY) Oct 26
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device Oct 11 Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device Oct 05
Biotricity, Inc. has completed a Follow-on Equity Offering. Sep 21
New major risk - Financial position Aug 17
First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023) Aug 16
Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement Aug 06
Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications Jul 26
Biotricity Regains Nasdaq Listing Compliance Jul 23
Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023 Jul 07
Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022) Jul 01
Third quarter 2023 earnings: Revenues exceed analyst expectations Feb 16
Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price Jan 23
Consensus revenue estimates fall by 19% Nov 21
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 16
Price target decreased to US$3.83 Nov 16
Less than half of directors are independent Nov 16
Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics Oct 27
Less than half of directors are independent Sep 29
Biotricity GAAP EPS of -$0.09, revenue of $2.06M Aug 15
Biotricity Announces Management Changes Aug 13
Biotricity, Inc.: A First Take Jul 28
Biotricity, Inc. announced delayed annual 10-K filing Jun 30
Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way? Apr 09
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Feb 15
Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022 Feb 10
High number of new directors Dec 31
Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet? Dec 11
High number of new directors Nov 17
Biotricity: Capital Raise Leads To Buying Opportunity Aug 31
Biotricity Common Stock Deleted from Other OTC Aug 27
Biotricity, Inc. announced delayed 10-Q filing Aug 18
Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022 Jun 18
Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021 Feb 09
Biotricity, Inc. announced that it has received $9.5575 million in funding Jan 22
Biotricity Announces New Solution for Personal Heart Management with Bioheart Jan 12
Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres Dec 03
Biotricity Inc. Announces Launch of Its Bioflux® Direct Program Sep 30
Biotricity, Inc. announced a financing transaction Aug 11 Shareholder Returns BTCY US Healthcare Services US Market 7D -11.4% -0.07% -2.4% 1Y -74.5% 1.9% 23.3%
See full shareholder returns
Return vs Market: BTCY underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is BTCY's price volatile compared to industry and market? BTCY volatility BTCY Average Weekly Movement 31.5% Healthcare Services Industry Average Movement 9.4% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: BTCY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BTCY's weekly volatility has increased from 22% to 31% over the past year.
About the Company Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components.
Show more Biotricity, Inc. Fundamentals Summary How do Biotricity's earnings and revenue compare to its market cap? BTCY fundamental statistics Market cap US$6.88m Earnings (TTM ) -US$16.05m Revenue (TTM ) US$12.62m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BTCY income statement (TTM ) Revenue US$12.62m Cost of Revenue US$3.36m Gross Profit US$9.26m Other Expenses US$25.31m Earnings -US$16.05m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.65 Gross Margin 73.40% Net Profit Margin -127.16% Debt/Equity Ratio -80.2%
How did BTCY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 03:41 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Biotricity, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kevin Dede H.C. Wainwright & Co. Jason Wittes Northland Capital Markets
Show 0 more analysts 
